To evaluate the effects of teriparatide followed by zoledronic acid on fracture rates and bone mineral density (BMD) in adults with osteogenesis imperfecta compared to standard care.
Key Findings:
No statistically significant reduction in imaging-confirmed fractures in the teriparatide plus zoledronic acid group compared to standard care.
Bone mineral density improved significantly in the intervention group, particularly at the lumbar spine and total hip.
Incident fractures occurred in 36.9% of the intervention group and 36.4% of the standard care group, with no significant difference.
Interpretation:
Limitations:
Fewer primary outcome fractures than expected limited the ability to detect a treatment effect.
No data on falls was collected.
Limited generalizability due to the study population being predominantly type I osteogenesis imperfecta patients.
